Prognostic Features of Long-term Survivors After Surgical Management of Malignant Pleural Mesothelioma

Annals of Thoracic Surgery

Volumn 87, Issue 5, 2009, Pages 1552-1556

  Yan, Tristan D ^a,b   Boyer, Michael ^a,c   Tin, Mo Mo ^a,c   Sim, Junyang ^a   Kennedy, Catherine ^a,b   McLean, Jocelyn ^a,b   Bannon, Paul G ^a,b   McCaughan, Brian C ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b Baird Institute for Applied Heart and Lung Surgical Research   (Australia)

^c SYDNEY CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DECORTICATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG BIOPSY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

AGED; BIOPSY; FEMALE; HUMANS; LYMPH NODES; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TIME FACTORS;

EID: 64649102733     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2009.01.026     Document Type: Article

References (13)

1. Price B., and Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159 (2004) 107-112
2. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N Engl J Med 353 (2005) 1591-1603
3. Muers M., Stephens R., Fisher P., et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 371 (2008) 1685-1694
4. Sugarbaker D., Flores R., Jaklitsch M., et al. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-65
5. Flores R., Pass H., Seshan V.E., et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135 (2008) 620-626
6. Yajnik S., Rosenzweig K.E., Mychalczak B., et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 56 (2003) 1319-1326
7. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
8. Ceresoli G.L., Zucali P.A., Favaretto A.G., et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 24 (2006) 1443-1448
9. Castagneto B., Botta M., Aitini E., et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 19 (2008) 370-373
10. Ceresoli G.L., Locati L.D., Ferreri A.J., et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34 (2001) 279-287
11. Brancatisano R., Joseph M., and McCaughan B. Pleurectomy for mesothelioma. Med J Aust 154 (1991) 455-460
12. Sugarbaker D.J. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol 1 (2006) 175-176
13. Flores R.M., Akhurst T., Gonen M., et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132 (2006) 763-768